Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Bioavailability Study of XC8 in Healthy Volunteers
NCT05294250Phase 1Completed
- Sponsor
- Valenta Pharm
- Start
- Feb 2022
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of histamine glutarimide in acute respiratory viral infection (ARVI) and cough (2 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Plasma Concentration (Cmax), Area Under the Curve from Time 0 to Last Quantifiable Concentration (AUC0-t) and 1 more. Started Feb 2022; status: completed.
02
Drugs
histamine glutarimide
03
Conditions
acute respiratory viral infection (ARVI)cough
Beyond the preview
Go deeper on NCT05294250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05294250.